Replies to post #7914 on InMed Pharmaceuticals Inc (INM)

[Fress]

Latest InMed Pharmaceuticals Presentation

Takeaways from presentation:

Biosynthesis potential disrupt the whole industry put the growers out of business.

6-12 Cannabinoids have been completed. 100% effective


Batting 1000%


Technology works & Technology extremely robust.

Industry Leaders from Biotech and Cultivation already calling InMed to supply them

Strong Patent Protection.


Strong research on each Cannabinoid


Biosynthesis ready 2019


INM-755 NO drug approved by the FDA to date. Human trials soon Phase 1 is only 6 weeks possibility to run straight to pivotal Study . 1 Billion Market

INM-405 Orofacial Pain

INM-085 Glaucoma seeking partner


InMed Seeking Dow or Nasdaq UP LISTING.


IMLFF

[Fress]

InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology
InMed Pharmaceuticals Inc. (CNW Group/InMed Pharmaceuticals Inc.)


InMed Pharmaceuticals Inc.
Mar 18, 2019, 07:25 ET

SHARE THIS ARTICLE


TSX: IN
OTCQX: IMLFF

VANCOUVER, March 18, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as an R&D pipeline of medications targeting diseases with high unmet medical needs, today announced the publication of the first in a series of pending patent applications directed to the Company's biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids.

International Patent Application No. PCT/CA2018/051074, which recently published as WO2019046941, entitled 'METABOLIC ENGINEERING OF E. COLI FOR THE BIOSYNTHESIS OF CANNABINOID PRODUCTS', addresses the enablement and maximization of cannabinoid production through optimization of the precursor substrates needed to support specific cannabinoid synthesis. This application, as well as two more recently-filed U.S. provisional patent applications, also cover various elements required to enable functional cannabinoid synthase production in an E. coli system. The Company will actively seek to convert these two follow-on provisional applications, and subsequent provisional patents from new patent families, into additional Patent Cooperation Treaty ("PCT") applications in all major commercial jurisdictions, in due course.

Eric Hsu, PhD, InMed's Senior Vice President, Preclinical Research and Development, stated, "The publication of our initial patent and the filing of two additional provisional patent applications supports InMed's continued expansion of intellectual property coverage for our proprietary biosynthesis program. InMed will continue to position itself at the forefront of this and other innovative technologies to enable the manufacturing of pharmaceutical grade cannabinoids through biosynthesis."

Vikramaditya G. Yadav, PhD, Scientific Advisor to InMed and Assistant Professor in the Department of Chemical & Biological Engineering and School of Biomedical Engineering at the University of British Columbia, added, "It gives us great pride to help fortify InMed's leadership position with this potentially transformational innovation in the manufacturing of pharmaceutical-grade cannabinoids." Dr. Yadav, a co-inventor of the patent applications, continued, "These collaborative innovations with InMed provide new avenues to drug manufacturing that may ultimately benefit patients via cannabinoid-based therapeutics."

About InMed:
InMed Pharmaceuticals is a biopharmaceutical company developing a proprietary biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids, as well as a pipeline of cannabinoid-based medications that target diseases with high unmet medical needs. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.

IMLFF